Benefit of Clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups

Andrzej Budaj, Salim Yusuf, Shamir R. Mehta, Keith A A Fox, Gianni Tognoni, Feng Zhao, Susan Chrolavicius, David Hunt, M. Keltai, Maria Grazia Franzosi

Research output: Contribution to journalArticle

211 Citations (Scopus)

Abstract

Background - The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial demonstrated that clopidogrel, given early and continued long term, was superior to placebo in patients with non-ST-elevation acute coronary syndromes receiving aspirin. The purpose of the present analysis was to estimate the treatment effect of clopidogrel in patients who were stratified according to their risk of future cardiovascular events. Methods and Results - Patients (n = 12 562) who presented within 24 hours after the onset of symptoms were randomized to receive clopidogrel (300 mg followed by 75 mg daily) or placebo in addition to aspirin for 3 to 12 months. Treatment effect was analyzed in various risk groups according to the Thrombolysis in Myocardial Infarction (TIMI) risk score. The TIMI risk model was validated in the CURE population (C statistic, 0.634). The primary composite outcome of cardiovascular death, myocardial infarction, or stroke increased proportionally with increasing risk according to the TIMI risk score. The impact of clopidogrel versus placebo on the rate of the primary outcome was as follows: low-risk group (TIMI score 0 to 2), 4.1% versus 5.7% (relative risk [RR], 0.71; 95% confidence interval [CI], 0.52 to 0.97; P

Original languageEnglish
Pages (from-to)1622-1626
Number of pages5
JournalCirculation
Volume106
Issue number13
DOIs
Publication statusPublished - Sep 24 2002

Fingerprint

clopidogrel
Acute Coronary Syndrome
Myocardial Infarction
Placebos
Aspirin
Unstable Angina
Population Characteristics

Keywords

  • Angina
  • Drugs
  • Platelet aggregation inhibitors
  • Risk factors

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Budaj, A., Yusuf, S., Mehta, S. R., Fox, K. A. A., Tognoni, G., Zhao, F., ... Franzosi, M. G. (2002). Benefit of Clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation, 106(13), 1622-1626. https://doi.org/10.1161/01.CIR.0000029926.71825.E2

Benefit of Clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. / Budaj, Andrzej; Yusuf, Salim; Mehta, Shamir R.; Fox, Keith A A; Tognoni, Gianni; Zhao, Feng; Chrolavicius, Susan; Hunt, David; Keltai, M.; Franzosi, Maria Grazia.

In: Circulation, Vol. 106, No. 13, 24.09.2002, p. 1622-1626.

Research output: Contribution to journalArticle

Budaj, A, Yusuf, S, Mehta, SR, Fox, KAA, Tognoni, G, Zhao, F, Chrolavicius, S, Hunt, D, Keltai, M & Franzosi, MG 2002, 'Benefit of Clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups', Circulation, vol. 106, no. 13, pp. 1622-1626. https://doi.org/10.1161/01.CIR.0000029926.71825.E2
Budaj, Andrzej ; Yusuf, Salim ; Mehta, Shamir R. ; Fox, Keith A A ; Tognoni, Gianni ; Zhao, Feng ; Chrolavicius, Susan ; Hunt, David ; Keltai, M. ; Franzosi, Maria Grazia. / Benefit of Clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. In: Circulation. 2002 ; Vol. 106, No. 13. pp. 1622-1626.
@article{eb2de594e55248f3a3b889e990165ec7,
title = "Benefit of Clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups",
abstract = "Background - The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial demonstrated that clopidogrel, given early and continued long term, was superior to placebo in patients with non-ST-elevation acute coronary syndromes receiving aspirin. The purpose of the present analysis was to estimate the treatment effect of clopidogrel in patients who were stratified according to their risk of future cardiovascular events. Methods and Results - Patients (n = 12 562) who presented within 24 hours after the onset of symptoms were randomized to receive clopidogrel (300 mg followed by 75 mg daily) or placebo in addition to aspirin for 3 to 12 months. Treatment effect was analyzed in various risk groups according to the Thrombolysis in Myocardial Infarction (TIMI) risk score. The TIMI risk model was validated in the CURE population (C statistic, 0.634). The primary composite outcome of cardiovascular death, myocardial infarction, or stroke increased proportionally with increasing risk according to the TIMI risk score. The impact of clopidogrel versus placebo on the rate of the primary outcome was as follows: low-risk group (TIMI score 0 to 2), 4.1{\%} versus 5.7{\%} (relative risk [RR], 0.71; 95{\%} confidence interval [CI], 0.52 to 0.97; P",
keywords = "Angina, Drugs, Platelet aggregation inhibitors, Risk factors",
author = "Andrzej Budaj and Salim Yusuf and Mehta, {Shamir R.} and Fox, {Keith A A} and Gianni Tognoni and Feng Zhao and Susan Chrolavicius and David Hunt and M. Keltai and Franzosi, {Maria Grazia}",
year = "2002",
month = "9",
day = "24",
doi = "10.1161/01.CIR.0000029926.71825.E2",
language = "English",
volume = "106",
pages = "1622--1626",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "13",

}

TY - JOUR

T1 - Benefit of Clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups

AU - Budaj, Andrzej

AU - Yusuf, Salim

AU - Mehta, Shamir R.

AU - Fox, Keith A A

AU - Tognoni, Gianni

AU - Zhao, Feng

AU - Chrolavicius, Susan

AU - Hunt, David

AU - Keltai, M.

AU - Franzosi, Maria Grazia

PY - 2002/9/24

Y1 - 2002/9/24

N2 - Background - The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial demonstrated that clopidogrel, given early and continued long term, was superior to placebo in patients with non-ST-elevation acute coronary syndromes receiving aspirin. The purpose of the present analysis was to estimate the treatment effect of clopidogrel in patients who were stratified according to their risk of future cardiovascular events. Methods and Results - Patients (n = 12 562) who presented within 24 hours after the onset of symptoms were randomized to receive clopidogrel (300 mg followed by 75 mg daily) or placebo in addition to aspirin for 3 to 12 months. Treatment effect was analyzed in various risk groups according to the Thrombolysis in Myocardial Infarction (TIMI) risk score. The TIMI risk model was validated in the CURE population (C statistic, 0.634). The primary composite outcome of cardiovascular death, myocardial infarction, or stroke increased proportionally with increasing risk according to the TIMI risk score. The impact of clopidogrel versus placebo on the rate of the primary outcome was as follows: low-risk group (TIMI score 0 to 2), 4.1% versus 5.7% (relative risk [RR], 0.71; 95% confidence interval [CI], 0.52 to 0.97; P

AB - Background - The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial demonstrated that clopidogrel, given early and continued long term, was superior to placebo in patients with non-ST-elevation acute coronary syndromes receiving aspirin. The purpose of the present analysis was to estimate the treatment effect of clopidogrel in patients who were stratified according to their risk of future cardiovascular events. Methods and Results - Patients (n = 12 562) who presented within 24 hours after the onset of symptoms were randomized to receive clopidogrel (300 mg followed by 75 mg daily) or placebo in addition to aspirin for 3 to 12 months. Treatment effect was analyzed in various risk groups according to the Thrombolysis in Myocardial Infarction (TIMI) risk score. The TIMI risk model was validated in the CURE population (C statistic, 0.634). The primary composite outcome of cardiovascular death, myocardial infarction, or stroke increased proportionally with increasing risk according to the TIMI risk score. The impact of clopidogrel versus placebo on the rate of the primary outcome was as follows: low-risk group (TIMI score 0 to 2), 4.1% versus 5.7% (relative risk [RR], 0.71; 95% confidence interval [CI], 0.52 to 0.97; P

KW - Angina

KW - Drugs

KW - Platelet aggregation inhibitors

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=0037167686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037167686&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000029926.71825.E2

DO - 10.1161/01.CIR.0000029926.71825.E2

M3 - Article

C2 - 12270853

AN - SCOPUS:0037167686

VL - 106

SP - 1622

EP - 1626

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 13

ER -